$2.65
Value $348M
CCCC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$2.65
Value $348M
$282.55
Value $681B
C4 Therapeutics (CCCC) has a market value of $348M and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, CCCC moved +7.3% and JNJ +47.5%. Dividend yield: CCCC none, JNJ 1.87%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
CCCC$348M
JNJ$681B
JNJ is 1,957 times CCCC
Revenue, 12 months
CCCC$32M
JNJ$99.3B
JNJ is 3,078 times CCCC
Net income, 12 months
CCCC-$91M
JNJ$16.1B
Operating margin
CCCC-315.9%
JNJ–
ROIC
CCCC-35.9%
JNJ12.4%
48.3 points apart
P/E
CCCC–
JNJ42.3
Dividend yield
CCCC0.0%
JNJ1.9%
1.9 points apart
5-year return
CCCC-93.6%
JNJ+98.6%
192.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
CCCC-93.6%
JNJ+98.6%
| Period | CCCCWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +7.3%Price +7.3% | +47.5%Price +44.2% |
| 3 years since November 16, 2023 | +45.6%+13.3% a yearPrice +45.6% | +105.0%+27.0% a yearPrice +88.2% |
| 5 years since November 15, 2021 | -93.6%-42.4% a yearPrice -93.6% | +98.6%+14.7% a yearPrice +72.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
CCCCC4 TherapeuticsJNJJohnson & Johnson
| Price | $2.65 | $282.55 |
|---|---|---|
| Market value | $348M | $681B |
| Enterprise value (EV) | $73M | $708B |
| P/E | – | 42.3 |
| P/E, 5-year median | – | 21.9 |
| P/B | 1.5 | 8.4 |
| EV/EBIT | – | 39.9 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | $32M | $99.3B |
|---|---|---|
| Net income, 12 months | -$91M | $16.1B |
| Free cash flow, 12 months | -$80M | $20.6B |
| Earnings per share, 12 months | -$0.63 | $6.59 |
| Revenue growth, year on year | 1.0% | 6.1% |
| Revenue growth a year, past | -5.9%over 4 years | +2.7%over 5 years |
| EPS growth a year, past | – | +14.9%over 5 years |
| Gross margin | – | 67.6% |
|---|---|---|
| Operating margin | -315.9% | – |
| Net margin | -282.2% | 16.2% |
| ROIC | -35.9% | 12.4% |
| ROE | -40.6% | 19.7% |
| Cash | $275M | $17.2B |
|---|---|---|
| Total debt | $55M | $44.7B |
| Net debt / EBITDA | – | 1.1 |
| Interest cover | – | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 0.1% | 0.9% |
| Shareholder yield | 0.1% | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($681B) is about 1,956.7 times C4 Therapeutics ($348M), at today's prices.
Since November 15, 2021, CCCC's price moved -93.6% and JNJ's +72.8%. With dividends: CCCC -93.6% (-42.4% a year), JNJ +98.6% (+14.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for C4 Therapeutics and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
Over the last twelve months, the net margin was -282.2% for C4 Therapeutics and 16.2% for Johnson & Johnson, and the operating margin -315.9% and –. Revenue was $32M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.